Abstract
Relevance. Community-acquired pneumonia and chronic obstructive pulmonary disease (COPD) remain a serious public health problem in all respects today.Aims. To summarize the studies of domestic authors on the study of the effect of pneumococcal polysaccharide vaccine on various parts of the immune system and their relationship with the clinical course of the disease in patients with COPD and community-acquired pneumonia. We also consider it necessary to discuss the possible mechanisms of therapeutic effects after the introduction of a monovaccine against S. pneumoniae, as well as when it is combined with vaccines against Haemophilus influenzae type b infection, and the effectiveness of various vaccination regimens, including complex ones.Conclusions. Convincing arguments are presented proving that the introduction of vaccines against respiratory infections can have not only a reventive value, but also a therapeutic effect, accompanied by a transient restoration of the immune system parameters, as well as a reduction in the contamination or elimination of S. pneumoniae in patients with chronic pathology of the bronchopulmonary system.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
